New York, NY, August 05, 2019 –(PR.com)– Quantum Genomics are the creators of Firibastat, a first-in-class brain aminopeptidase inhibitor (BAPAI) that could potentially treat treatment-resistant hypertension by acting in the brain to interfere with the renin-angiotensin system.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
